JP2001518118A - ヒト肥満細胞活性化のモジュレーション - Google Patents
ヒト肥満細胞活性化のモジュレーションInfo
- Publication number
- JP2001518118A JP2001518118A JP54597398A JP54597398A JP2001518118A JP 2001518118 A JP2001518118 A JP 2001518118A JP 54597398 A JP54597398 A JP 54597398A JP 54597398 A JP54597398 A JP 54597398A JP 2001518118 A JP2001518118 A JP 2001518118A
- Authority
- JP
- Japan
- Prior art keywords
- purinoceptor
- mast cells
- atp
- cells
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4146197P | 1997-03-25 | 1997-03-25 | |
| US60/041,461 | 1997-03-25 | ||
| PCT/US1998/005922 WO1998042353A1 (en) | 1997-03-25 | 1998-03-24 | Modulation of human mast cell activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001518118A true JP2001518118A (ja) | 2001-10-09 |
| JP2001518118A5 JP2001518118A5 (cg-RX-API-DMAC7.html) | 2005-11-24 |
Family
ID=21916643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54597398A Ceased JP2001518118A (ja) | 1997-03-25 | 1998-03-24 | ヒト肥満細胞活性化のモジュレーション |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6372724B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1011686B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2001518118A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE470441T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU741713B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2288821C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69841711D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1011686T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998042353A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288821C (en) * | 1997-03-25 | 2008-10-14 | Allegheny University Of The Health Sciences | Modulation of human mast cell activation |
| DK1187617T3 (da) * | 1999-06-18 | 2004-04-13 | Alcon Mfg Ltd | Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal |
| GB9916757D0 (en) | 1999-07-17 | 1999-09-15 | Glaxo Group Ltd | Method |
| EP1269198A2 (en) * | 2000-03-23 | 2003-01-02 | Novartis AG | Identification of mast/basophil activation inhibitors |
| US20040072865A1 (en) * | 2001-01-15 | 2004-04-15 | Bouillot Anne Marie Jeanne | Aryl piperidine derivatives as inducers of ldl-receptor expression |
| JP2004520347A (ja) * | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| EP1351937A1 (en) * | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine derivatives as inducers of ldl-receptor expression |
| MXPA04004215A (es) * | 2001-11-06 | 2004-07-08 | Inspire Pharmaceuticals Inc | Metodo para el tratamiento o la prevencion de enfermedades inflamatorias. |
| WO2003070902A2 (en) * | 2002-02-20 | 2003-08-28 | Incyte Corporation | Receptors and membrane-associated proteins |
| US20070276126A1 (en) * | 2002-08-13 | 2007-11-29 | Incyte Corporation | Cell adhesion and extracellular matrix proteins |
| US20070219353A1 (en) * | 2002-09-03 | 2007-09-20 | Incyte Corporation | Immune Response Associated Proteins |
| AU2003279829A1 (en) * | 2002-10-04 | 2004-05-04 | Incyte Corp | Protein modification and maintenance molecules |
| AU2003300785A1 (en) * | 2002-11-12 | 2004-06-03 | Incyte Corporation | Carbohydrate-associated proteins |
| AU2003295462A1 (en) * | 2002-11-13 | 2004-06-03 | Incyte Corporation | Lipid-associated proteins |
| AU2003302234A1 (en) * | 2002-11-26 | 2004-06-18 | Incyte Corporation | Immune response associated proteins |
| WO2004098539A2 (en) | 2003-04-30 | 2004-11-18 | Incyte Corporation | Kinases and phosphatases |
| WO2006012639A2 (en) * | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| EP1910535B1 (en) | 2005-06-24 | 2016-08-17 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same |
| GB0601058D0 (en) * | 2006-01-19 | 2006-03-01 | Univ Southampton | Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis |
| CA2680801A1 (en) * | 2007-03-14 | 2008-09-18 | Sierra Molecular Corporation | Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| US10107795B2 (en) | 2012-10-25 | 2018-10-23 | The United States Of America As Represented By The Department Of Veterans Affairs | Composition and methods for the prevention and treatment of diet-induced obesity |
| US10614684B2 (en) | 2017-01-31 | 2020-04-07 | The United States Government As Represented By The | Treatment of kidney diseases associated with elevated AVP |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53148539A (en) * | 1977-05-30 | 1978-12-25 | Fujisawa Pharmaceut Co Ltd | Antiallergic agnet |
| US5158940A (en) * | 1990-02-14 | 1992-10-27 | The United States Government As Represented By The Secretary, Dhhs | Use of suramin to treat rheumatologic diseases |
| US5504090A (en) * | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
| EP0760850A1 (en) * | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
| US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| US5874420A (en) | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
| CA2288821C (en) * | 1997-03-25 | 2008-10-14 | Allegheny University Of The Health Sciences | Modulation of human mast cell activation |
-
1998
- 1998-03-24 CA CA002288821A patent/CA2288821C/en not_active Expired - Fee Related
- 1998-03-24 WO PCT/US1998/005922 patent/WO1998042353A1/en not_active Ceased
- 1998-03-24 AU AU70985/98A patent/AU741713B2/en not_active Ceased
- 1998-03-24 AT AT98917959T patent/ATE470441T1/de active
- 1998-03-24 DE DE69841711T patent/DE69841711D1/de not_active Expired - Lifetime
- 1998-03-24 US US09/381,692 patent/US6372724B1/en not_active Expired - Fee Related
- 1998-03-24 EP EP98917959A patent/EP1011686B9/en not_active Expired - Lifetime
- 1998-03-24 JP JP54597398A patent/JP2001518118A/ja not_active Ceased
- 1998-03-24 DK DK98917959.3T patent/DK1011686T3/da active
-
2001
- 2001-12-20 US US10/027,052 patent/US6465441B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE470441T1 (de) | 2010-06-15 |
| WO1998042353A1 (en) | 1998-10-01 |
| US6465441B2 (en) | 2002-10-15 |
| US6372724B1 (en) | 2002-04-16 |
| EP1011686B9 (en) | 2011-02-09 |
| EP1011686B1 (en) | 2010-06-09 |
| EP1011686A4 (en) | 2003-03-19 |
| CA2288821A1 (en) | 1998-10-01 |
| AU7098598A (en) | 1998-10-20 |
| DE69841711D1 (de) | 2010-07-22 |
| AU741713B2 (en) | 2001-12-06 |
| DK1011686T3 (da) | 2010-10-11 |
| US20020055515A1 (en) | 2002-05-09 |
| CA2288821C (en) | 2008-10-14 |
| EP1011686A1 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6465441B2 (en) | Screening method for modulation of human mast cell activation | |
| Bowery et al. | (–) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor | |
| Guerrero | A2A adenosine receptor agonists and their potential therapeutic applications. An update | |
| Kolachala et al. | Purinergic receptors in gastrointestinal inflammation | |
| Partida-Sánchez et al. | Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity | |
| Sihra et al. | Effect of cyclosporin A on the allergen-induced late asthmatic reaction. | |
| Guan et al. | Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target | |
| Rabe et al. | Theophylline and airway inflammation. | |
| HUP0200026A2 (hu) | Eljárás terhelés által indukált asztma kezelésére | |
| Brenner et al. | Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556 | |
| Michael et al. | Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations | |
| Gabriella Matera et al. | New treatments for COPD in the elderly | |
| Arm et al. | Expression of complement receptors type 1 (CR1) and type 3 (CR3) on circulating granulocytes in experimentally provoked asthma | |
| Kaelin et al. | Influence of ethanol on human T-lymphocyte migration | |
| Spitzer et al. | Protein tyrosine kinase activity and the influence of gender in phagocytosis and tumor necrosis factor secretion in alveolar macrophages and lung-recruited neutrophils | |
| WO2017157248A1 (zh) | 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用 | |
| US5492898A (en) | Method of treating endotoxin effects with 2-methylthio-ATP and analogs | |
| Middleton Jr et al. | Cellular mechanisms in the pathogenesis and pathophysiology of asthma | |
| WO1995010287A1 (en) | Substituted purine nucleoside analogs and method for treating endotoxin shock | |
| JP2002530355A (ja) | 炎症性疾患のための治療剤としてのαEβ7インテグリンのアンタゴニスト | |
| Kadioglu et al. | Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion. | |
| Coffey et al. | Increased adenosine triphosphatase activity in platelets of asthmatic children | |
| Walker | Effects of adenosine on guinea pig pulmonary eosinophils | |
| US5516762A (en) | Method of treating endotoxin effects with 2-haloadenosine nucleotide analogs | |
| WO1992017186A1 (en) | Compounds that prevent endotoxin shock and method of using the compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081111 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090106 |